We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+8.09%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$2.01B
AUM Growth
+$465M
Cap. Flow
+$371M
Cap. Flow %
18.41%
Top 10 Hldgs %
74.76%
Holding
43
New
8
Increased
4
Reduced
13
Closed
1

Top Buys

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$137M
2
NKTX icon
Nkarta
NKTX
+$82.3M
3
CTLT
CATALENT, INC.
CTLT
+$67.7M
4
INZY
Inozyme Pharma
INZY
+$63.8M
5
CMPI
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
+$27.8M

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$28.5M
2
PCVX icon
Vaxcyte
PCVX
+$9.18M
3
CRVS icon
Corvus Pharmaceuticals
CRVS
+$6.15M
4
SIBN icon
SI-BONE Inc
SIBN
+$5.79M
5
ETTX
Entasis Therapeutics Holdings Inc.
ETTX
+$2.93M

Sector Composition

Rank Sector Weight
1 Healthcare 54.36%
2 Technology 7.2%
3 Communication Services 5.36%
4 Financials 5.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRNA
26
DELISTED
Verona Pharma
VRNA
$11.2M 0.56%
1,800,747
+1,060,007
+143% +$7.32M
AKUS
27
DELISTED
Akouos Inc
AKUS
$10.5M 0.52%
458,606
-9,180
-2% -$204K
SPRO icon
28
Spero Therapeutics
SPRO
$73M
$10.4M 0.52%
931,099
– –
FRLN
29
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$10.4M 0.52%
+44,333
New +$11.1M
AERI
30
DELISTED
Aerie Pharmaceuticals
AERI
$9.51M 0.47%
807,656
– –
CVAC
31
DELISTED
CureVac
CVAC
$9.39M 0.47%
+201,642
New +$11.2M
SILK
32
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$8.43M 0.42%
125,428
-20,000
-14% -$1.09M
XENT
33
DELISTED
Intersect ENT, Inc
XENT
$8.38M 0.42%
513,515
-45,000
-8% -$815K
INSP icon
34
Inspire Medical Systems
INSP
$1.74B
$7.7M 0.38%
59,645
-19,891
-25% -$2.19M
AFIB
35
DELISTED
Acutus Medical Inc
AFIB
$7.6M 0.38%
+255,000
New +$7.74M
ZGNX
36
DELISTED
Zogenix, Inc.
ZGNX
$5.84M 0.29%
325,814
– –
CRVS icon
37
Corvus Pharmaceuticals
CRVS
$1.17B
$5.57M 0.28%
1,389,498
-1,538,062
-53% -$6.15M
BHVN
38
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$5.5M 0.27%
84,600
– –
NARI
39
DELISTED
Inari Medical, Inc. Common Stock
NARI
$5.21M 0.26%
75,500
– –
AKBA icon
40
Akebia Therapeutics
AKBA
$252M
$4.99M 0.25%
1,987,506
– –
CRNX icon
41
Crinetics Pharmaceuticals
CRNX
$8.92B
$4.25M 0.21%
271,378
+56,925
+27% +$870K
ETTX
42
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$2.35M 0.12%
1,153,911
-1,027,932
-47% -$2.93M
STIM icon
43
Neuronetics
STIM
$166M
– –
-514,190
Closed -$992K
1
2

Similar funds

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.24B AUM 16.52% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return
SPC
Stony Point Capital New York $1.24B AUM 32.69% 1-Year Est. Return
SC
Strategy Capital Los Altos, California $1.22B AUM 27.02% 1-Year Est. Return

Novo Holdings A/S's Q3 2020 Portfolio in Review

As of Q3 2020, Novo Holdings A/S held 43 positions worth $2.01B, up 30% from $1.55B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Novo Holdings A/S deployed $371M of net new capital in Q3 2020, opening 8 new positions and adding to 4 existing holdings. Its largest new stake was Harmony Biosciences: 3,754,973 shares worth $127M.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, up from 45% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Apple, an estimated $28.5M trimmed.

  • Novo Holdings A/S's largest Q3 2020 buy was Harmony Biosciences: 3,754,973 shares worth $127M.
  • Novo Holdings A/S added most to CATALENT, INC. in Q3 2020, an estimated $67.7M increase.
  • Novo Holdings A/S's biggest Q3 2020 reduction was Apple, cutting an estimated $28.5M.
  • Novo Holdings A/S fully exited Neuronetics in Q3 2020, selling an estimated $992K.
  • Novo Holdings A/S's ten largest holdings make up 75% of its $2.01B portfolio in Q3 2020.
  • Novo Holdings A/S opened 8 new positions and closed 1 in Q3 2020.
  • Novo Holdings A/S's portfolio value rose 30% quarter-over-quarter to $2.01B.

Based on Novo Holdings A/S's 13F filing for Q3 2020, filed 16 Nov 2020.